{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:05:38Z","timestamp":1790345138602,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010763","name":"Zorginstituut Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40273-026-01637-w","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:02:54Z","timestamp":1783411374000},"page":"1267-1280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use and Outcomes of Cost-Effectiveness Analyses and Additional Considerations in Pharmaceutical Reimbursement in the Netherlands"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0100-1040","authenticated-orcid":false,"given":"Diederik","family":"Brokkelkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-3431","authenticated-orcid":false,"given":"Vivian","family":"Reckers-Droog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-814X","authenticated-orcid":false,"given":"Lonneke","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-2393","authenticated-orcid":false,"given":"Pieter","family":"van Baal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"1637_CR1","doi-asserted-by":"publisher","unstructured":"OECD. Health at a Glance 2023: OECD Indicators. OECD; 2023. https:\/\/doi.org\/10.1787\/7a7afb35-en.","DOI":"10.1787\/7a7afb35-en"},{"key":"1637_CR2","unstructured":"Centraal Bureau voor de Statistiek. Uitgaven gezondheids-, welzijnszorg; zorgaanbieders, financiering, 1998\u20132022. 2024. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/84053ned. Accessed May 21, 2025."},{"key":"1637_CR3","unstructured":"Centraal Bureau voor de Statistiek. Bbp, productie en bestedingen; kwartalen, mutaties, na, 1995-2024-I. 2024. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/84106NED. Accessed May 21, 2025."},{"key":"1637_CR4","doi-asserted-by":"publisher","unstructured":"Chernew ME, Newhouse JP. Health Care Spending Growth. In: Handbook of health economics, vol 2. Elsevier; 2011. p. 1\u201343. https:\/\/doi.org\/10.1016\/B978-0-444-53592-4.00001-3.","DOI":"10.1016\/B978-0-444-53592-4.00001-3"},{"issue":"4","key":"1637_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10433-013-0280-x","volume":"10","author":"C De Meijer","year":"2013","unstructured":"De Meijer C, Wouterse B, Polder J, Koopmanschap M. The effect of population aging on health expenditure growth: a critical review. Eur J Ageing. 2013;10(4):353\u201361. https:\/\/doi.org\/10.1007\/s10433-013-0280-x.","journal-title":"Eur J Ageing"},{"issue":"6","key":"1637_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hec.4500","volume":"31","author":"M Laudicella","year":"2022","unstructured":"Laudicella M, Li Donni P, Olsen KR, Gyrd-Hansen D. Age, morbidity, or something else? A residual approach using microdata to measure the impact of technological progress on health care expenditure. Health Econ. 2022;31(6):1184\u2013201. https:\/\/doi.org\/10.1002\/hec.4500.","journal-title":"Health Econ"},{"issue":"4","key":"1637_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/jmahp12040031","volume":"12","author":"C Ntais","year":"2024","unstructured":"Ntais C, Talias MA, Fanourgiakis J, Kontodimopoulos N. Managing pharmaceutical costs in health systems: a review of affordability, accessibility and sustainability strategies. J Mark Access Health Policy. 2024;12(4):403\u201314. https:\/\/doi.org\/10.3390\/jmahp12040031.","journal-title":"J Mark Access Health Policy."},{"issue":"21","key":"1637_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1001\/jama.2022.5542","volume":"327","author":"BN Rome","year":"2022","unstructured":"Rome BN, Egilman AC, Kesselheim AS. Trends in prescription drug launch prices, 2008\u20132021. JAMA. 2022;327(21):2145\u20137. https:\/\/doi.org\/10.1001\/jama.2022.5542.","journal-title":"JAMA"},{"issue":"1","key":"1637_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hec.3130","volume":"24","author":"K Claxton","year":"2015","unstructured":"Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is nice failing to uphold its responsibilities to all Nhs patients? Health Econ. 2015;24(1):1\u20137. https:\/\/doi.org\/10.1002\/hec.3130.","journal-title":"Health Econ"},{"key":"1637_CR10","doi-asserted-by":"publisher","unstructured":"Morgan SG, Bathula HS, Moon S. Pricing of pharmaceuticals is becoming a major challenge for health systems. 2020. https:\/\/doi.org\/10.1136\/bmj.l4627.","DOI":"10.1136\/bmj.l4627"},{"issue":"4","key":"1637_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1017\/S1744133120000237","volume":"16","author":"JJ Enzing","year":"2021","unstructured":"Enzing JJ, Knies S, Boer B, Brouwer WBF. Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride? Health Econ Policy Law. 2021;16(4):440\u201356. https:\/\/doi.org\/10.1017\/S1744133120000237.","journal-title":"Health Econ Policy Law"},{"key":"1637_CR12","doi-asserted-by":"publisher","unstructured":"Garber AM, Sculpher MJ. Cost effectiveness and payment policy. In: Handbook of health economics. Elsevier; 2011. p. 471\u201397. https:\/\/doi.org\/10.1016\/B978-0-444-53592-4.00008-6.","DOI":"10.1016\/B978-0-444-53592-4.00008-6"},{"issue":"8","key":"1637_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jval.2016.08.001","volume":"19","author":"M Franken","year":"2016","unstructured":"Franken M, Heintz E, Gerber-Grote A, Raftery J. Health economics as rhetoric: the limited impact of health economics on funding decisions in four European countries. Value Health. 2016;19(8):951\u20136. https:\/\/doi.org\/10.1016\/j.jval.2016.08.001.","journal-title":"Value Health."},{"issue":"10","key":"1637_CR14","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/hec.3086","volume":"24","author":"H Dakin","year":"2015","unstructured":"Dakin H, Devlin N, Feng Y, Rice N, O\u2019Neill P, Parkin D. The influence of cost-effectiveness and other factors on nice decisions. Health Econ. 2015;24(10):1256\u201371. https:\/\/doi.org\/10.1002\/hec.3086.","journal-title":"Health Econ"},{"issue":"7","key":"1637_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.zefq.2014.06.016","volume":"108","author":"M Franken","year":"2014","unstructured":"Franken M, Koopmanschap M, Steenhoek A. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously? Z F\u00fcr Evidenz Fortbild Qual Im Gesundheitswesen. 2014;108(7):383\u20139. https:\/\/doi.org\/10.1016\/j.zefq.2014.06.016.","journal-title":"Z F\u00fcr Evidenz Fortbild Qual Im Gesundheitswesen."},{"issue":"7","key":"1637_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.zefq.2014.08.018","volume":"108","author":"A Gerber-Grote","year":"2014","unstructured":"Gerber-Grote A, Windeler J. What is the contribution of health economic evaluations to decision-making in health care? Experiences from 7 selected countries. Z F\u00fcr Evidenz Fortbild Qual Im Gesundheitswesen. 2014;108(7):358\u20139. https:\/\/doi.org\/10.1016\/j.zefq.2014.08.018.","journal-title":"Z F\u00fcr Evidenz Fortbild Qual Im Gesundheitswesen."},{"issue":"3","key":"1637_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40258-014-0132-7","volume":"13","author":"G Merlo","year":"2015","unstructured":"Merlo G, Page K, Ratcliffe J, Halton K, Graves N. Bridging the gap: exploring the barriers to using economic evidence in healthcare decision making and strategies for improving uptake. Appl Health Econ Health Policy. 2015;13(3):303\u20139. https:\/\/doi.org\/10.1007\/s40258-014-0132-7.","journal-title":"Appl Health Econ Health Policy"},{"key":"1637_CR18","unstructured":"Kuipers E. Geneesmiddelenbeleid; Brief regering; Wijziging beleidsregels voor de toepassing van de sluis voor dure geneesmiddelen op grond van artikel 2.4a van het Besluit zorgverzekering. 2023. https:\/\/zoek.officielebekendmakingen.nl\/kst-29477-798. Accessed 19 Aug 2025."},{"key":"1637_CR19","unstructured":"Ministerie van Volksgezondheid Welzijn en Sport. Besluit van 23 april 2018, houdende wijziging van het Besluit zorgverzekering in verband met regels voor de toelating van geneesmiddelen tot het basispakket. Ministerie van Justitie en Veiligheid; 2018. https:\/\/zoek.officielebekendmakingen.nl\/stb-2018-131.html."},{"key":"1637_CR20","unstructured":"Zwaap J, Knies S, van der Meijden C, Staal P, van der Heiden L. Kosteneffectiviteit in de Praktijk. Zorginstituut Nederland; 2015."},{"key":"1637_CR21","unstructured":"de Boer JE, Pasman P. Procedure beoordeling extramurale geneesmiddelen\u2014Rapport\u2014Zorginstituut Nederland. Ministerie van Volksgezondheid, Welzijn en Sport; 2018. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2018\/11\/21\/procedure-beoordeling-extramurale-geneesmiddelen."},{"key":"1637_CR22","unstructured":"Zorginstituut Nederland. GIP databank. https:\/\/www.gipdatabank.nl\/. Accessed 2 June 2025."},{"key":"1637_CR23","unstructured":"Enzing, Knies S, Zwaap J. Beoordelingskader Kosteneffectiviteit van Zorg: Afweging van Effecten En Kosten. Zorginstituut Nederland; 2024. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2024\/11\/26\/beoordelingskader-kosteneffectiviteit-van-zorg."},{"key":"1637_CR24","unstructured":"Zwaap J, Kooijman H. Pakketbeheer in de Praktijk 4: Pakketbeheer Als Solide Basis Voor Passende Zorg. Zorginstituut Nederland; 2023. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2023\/03\/20\/pip4."},{"key":"1637_CR25","unstructured":"Zorginstituut Nederland. Beoordeling stand van de wetenschap en praktijk 2023. Ministerie van Volksgezondheid, Welzijn en Sport; 2023. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2023\/04\/11\/beoordeling-swp-2023."},{"key":"1637_CR26","unstructured":"Borst-Eliers E. Wijziging bijlagen Regeling farmaceutische hulp 1996. Ministerie van Binnenlandse Zaken en Koninkrijksrelaties; 2000. https:\/\/zoek.officielebekendmakingen.nl\/stcrt-2000-69-p10-SC23486.html."},{"key":"1637_CR27","unstructured":"Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg (versie 2024). Zorginstituut Nederland; 2024. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg."},{"key":"1637_CR28","unstructured":"Vijgen S, van Heesch F, Obradovic M. Ziektelast in de Praktijk. De Theorie En Praktijk van Het Berekenen van Ziektelast Bij Pakketbeoordelingen. Zorginstituut Nederland; 2018."},{"key":"1637_CR29","unstructured":"Zorginstituut Nederland. Afwegingskader Noodzakelijk Te Verzekeren. Zorginstituut Nederland; 2023."},{"key":"1637_CR30","unstructured":"Zorginstituut Nederland. Afwegingskader uitvoerbaarheid van zorg. 2025."},{"key":"1637_CR31","unstructured":"Adviescommissie Pakket. Argumentenkader Dure Geneesmiddelen | Zorginstituut Nederland. Ministerie van Volksgezondheid, Welzijn en Sport; 2024. https:\/\/www.zorginstituutnederland.nl\/documenten\/2024\/02\/05\/argumentenkader-voor-dure-geneesmiddelen. Accessed 27 Feb 2026."},{"issue":"3","key":"1637_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/11539850-000000000-00000","volume":"30","author":"T Hoomans","year":"2012","unstructured":"Hoomans T, Severens JL, Van Der Roer N, Delwel GO. Methodological quality of economic evaluations of new pharmaceuticals in the Netherlands. Pharmacoeconomics. 2012;30(3):219\u201327. https:\/\/doi.org\/10.2165\/11539850-000000000-00000.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1637_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40273-013-0074-1","volume":"31","author":"M Franken","year":"2013","unstructured":"Franken M, Nilsson F, Sandmann F, De Boer A, Koopmanschap M. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making. Pharmacoeconomics. 2013;31(9):781\u201397. https:\/\/doi.org\/10.1007\/s40273-013-0074-1.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1637_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2021.08.003","volume":"25","author":"M Schurer","year":"2022","unstructured":"Schurer M, Matthijsse SM, Vossen CY, et al. Varying willingness to pay based on severity of illness: impact on health technology assessment outcomes of inpatient and outpatient drug therapies in the Netherlands. Value Health. 2022;25(1):91\u2013103. https:\/\/doi.org\/10.1016\/j.jval.2021.08.003.","journal-title":"Value Health."},{"key":"1637_CR35","unstructured":"Zorginstituut Nederland. Publicaties\u2014Zorginstituut Nederland. https:\/\/www.zorginstituutnederland.nl\/publicaties."},{"key":"1637_CR36","unstructured":"Zorginstituut Nederland. Procedure voorwaardelijke toelating weesgeneesmiddelen, conditionals, exceptionals. 2023. https:\/\/www.zorginstituutnederland.nl\/documenten\/2023\/09\/29\/procedure-voorwaardelijke-toelating-weesgeneesmiddelen-conditionals-exceptionals."},{"key":"1637_CR37","unstructured":"Zorginstituut Nederland. Pakketadvies osimertinib (Tagrisso\u00ae) bij de behandeling van pati\u00ebnten met gevorderde of gemetastaseerde niet-kleincellige longkanker (NSCLC) met activerende EGFR-mutaties (herbeoordeling) | Zorginstituut Nederland. Ministerie van Volksgezondheid, Welzijn en Sport; 2020. https:\/\/www.zorginstituutnederland.nl\/documenten\/2020\/09\/21\/pakketadvies-herbeoordeling-osimertinib-tagrisso."},{"key":"1637_CR38","unstructured":"Zorginstituut Nederland. Pakketadvies sluisgeneesmiddel sacituzumab govitecan (Trodelvy\u00ae) voor de behandeling van inoperabele of uitgezaaide borstkanker | Zorginstituut Nederland. Ministerie van Volksgezondheid, Welzijn en Sport; 2022. https:\/\/www.zorginstituutnederland.nl\/documenten\/2022\/07\/15\/pakketadvies-sacituzumab-govitecan-trodelvy."},{"key":"1637_CR39","unstructured":"Zorginstituut Nederland. Pakketadvies sluisgeneesmiddelen ipilimumab (Yervoy\u00ae) in combinatie met nivolumab (Opdivo\u00ae) bij de eerstelijnsbehandeling van gevorderd niercelcarcinoom | Zorginstituut Nederland. Ministerie van Volksgezondheid, Welzijn en Sport; 2019. https:\/\/www.zorginstituutnederland.nl\/documenten\/2019\/05\/29\/pakketadvies-sluisgeneesmiddelen-ipilimumab-yervoy-in-combinatie-met-nivolumab-opdivo."},{"issue":"1","key":"1637_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jval.2025.07.027","volume":"29","author":"APH Klockhoff","year":"2026","unstructured":"Klockhoff APH, Siverskog J, Henriksson M. Pharmaceutical pricing evidence from a healthcare system with multiple cost-per-quality-adjusted life-year thresholds. Value Health J Int Soc Pharmacoecon Outcomes Res. 2026;29(1):92\u20139. https:\/\/doi.org\/10.1016\/j.jval.2025.07.027.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res."},{"key":"1637_CR41","unstructured":"Dijkstra P. Nr. 898 Brief Van De Minister Voor Medische Zorg. 2024. https:\/\/www.rijksoverheid.nl\/documenten\/kamerstukken\/2024\/06\/13\/kamerbrief-over-voortgangsbrief-financiele-arrangementen-geneesmiddelen-2023."},{"key":"1637_CR42","unstructured":"Agema F. Voortgangsbrief financi\u00eble arrangementen geneesmiddelen 2024\u2014Kamerstuk\u2014Rijksoverheid.nl. 2025. https:\/\/www.rijksoverheid.nl\/documenten\/kamerstukken\/2025\/05\/19\/kamerbrief-over-voortgangsbrief-financiele-arrangementen-geneesmiddelen-2024."},{"key":"1637_CR43","unstructured":"Maatschappelijk Aanvaardbare Uitgaven Geneesmiddelen. Towards societally acceptable prices for expensive medicines. 2025. https:\/\/www.maug.nl\/."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01637-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01637-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01637-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:42:35Z","timestamp":1790343755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01637-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01637-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mr. Brokkelkamp reports grants from the National Health Care Institute (\n                      Zorginstituut Nederland\n                      , ZIN) during the conduct of the study. Dr. Reckers-Droog reports grants from ZIN during the conduct of the study. Dr. Timmers reports being employed by ZIN during the conduct of this study. Dr. Van Baal reports grants from ZIN during the conduct of the study and being a member of the Insured Package Advisory Committee (ACP) during the conduct of this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are made available in the Electronic Supplementary Material (Online Resource 1).","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualisation: DB, VR-D, LT, and PvB. Data curation: DB. Formal analysis: DB. Funding acquisition: PvB. Methodology: DB, VR-D, and PvB. Project administration: DB. Supervision: PvB, VR-D, and LT. Validation: DB, VR-D, LT, and PvB. Visualisation: DB. Writing\u2014original draft: DB. Writing\u2014review and editing: DB, VR-D, LT, and PvB.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}